Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ.

Eur J Cancer. 2009 May;45(7):1201-8. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14.

PMID:
19232484
2.

Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.

Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF.

J Natl Cancer Inst. 2011 Dec 21;103(24):1871-83. doi: 10.1093/jnci/djr438. Epub 2011 Oct 27.

3.

The MINDACT trial: the first prospective clinical validation of a genomic tool.

Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium.

Mol Oncol. 2007 Dec;1(3):246-51. doi: 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22.

4.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.

Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

PMID:
17019432
5.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC.

Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Erratum in: Lancet Oncol. 2008 Jan;9(1):10.

PMID:
18042430
6.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

7.

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.

Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA Jr.

Breast Cancer Res Treat. 2009 Dec;118(3):635-43. doi: 10.1007/s10549-008-0301-1. Epub 2009 Feb 18.

8.

MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.

Slodkowska EA, Ross JS.

Expert Rev Mol Diagn. 2009 Jul;9(5):417-22. doi: 10.1586/erm.09.32. Review.

PMID:
19580427
9.

Impact of biospecimens handling on biomarker research in breast cancer.

De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, Valeri B, Pierotti MA, Daidone MG.

BMC Cancer. 2009 Nov 24;9:409. doi: 10.1186/1471-2407-9-409.

10.

Clinical application of the 70-gene profile: the MINDACT trial.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.

J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

PMID:
18258980
11.

A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.

Brandão RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, Tjan-Heijnen VC, Hupperets PS.

Breast Cancer Res. 2013 Apr 8;15(2):R29. doi: 10.1186/bcr3409.

12.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ.

Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22.

PMID:
20094918
13.

Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue.

Mittempergher L, de Ronde JJ, Nieuwland M, Kerkhoven RM, Simon I, Rutgers EJ, Wessels LF, Van't Veer LJ.

PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163.

14.

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart M, Tursz T, Delaloge S, van't Veer L.

Breast. 2013 Oct;22(5):682-90. doi: 10.1016/j.breast.2012.12.002. Epub 2013 Jan 21.

PMID:
23347730
15.

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.

Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27.

PMID:
18661261
16.

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A.

Breast Cancer Res Treat. 2016 Apr;156(2):279-87. doi: 10.1007/s10549-016-3764-5. Epub 2016 Mar 22.

17.

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.

Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K.

BMC Cancer. 2008 Sep 8;8:254. doi: 10.1186/1471-2407-8-254.

18.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
19.

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

Retèl VP, Joore MA, Drukker CA, Bueno-de-Mesquita JM, Knauer M, van Tinteren H, Linn SC, van Harten WH.

Eur J Cancer. 2013 Dec;49(18):3773-9. doi: 10.1016/j.ejca.2013.08.001. Epub 2013 Aug 27.

PMID:
23992641
20.

Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.

Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB.

Breast Cancer Res Treat. 2010 Sep;123(2):397-404. doi: 10.1007/s10549-009-0654-0. Epub 2009 Dec 1.

Supplemental Content

Support Center